Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAH
STRONG BUYGet insider-trade alertsCardinal Health, Inc. · Healthcare · United States · $55.7B · Avg Vol: $543M/d
COMPANY DESCRIPTION
Cardinal Health, Inc. is a global integrated healthcare services and products company, playing a critical role in the healthcare supply chain through pharmaceutical and medical products distribution. The company's immense scale and extensive logistical network provide an indispensable link between manufacturers and healthcare providers, ensuring efficient delivery of essential supplies. This market position, alongside its portfolio of medical products, creates a significant competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 181.3B | 205.0B | 226.8B | 222.6B | 7.1% | 250.7B | 255.9B | 277.3B | 11.6% |
| EPS | -3.35 | 1.00 | 3.48 | 6.48 | 154.6% | 6.54 | 10.77 | 12.00 | 36.1% |
| Shares | 327.0M | 327.0M | 327.0M | 270.7M | -17.2% | 234.2M | — | — | — |
| Debt | 5.3B | 4.7B | 5.1B | 8.5B | 17.1% | 8.9B | — | — | — |
| Equity | -709.0M | -3.0B | -3.2B | -2.8B | — | — | — | — | — |
| Op CF | 3.2B | 2.8B | 3.8B | 2.4B | -8.9% | 5.0B | — | — | — |
| Inv CF | 567.0M | -454.0M | -1.8B | -5.6B | — | — | — | — | — |
| Fin CF | -2.5B | -3.1B | -847.0M | 1.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAH | Cardinal Health, Inc.(you) | $55.7B | 90 | STRONG BUY |
| MCK | McKesson Corporation | $89.4B | 84 | STRONG BUY |
| COR.MX | Cencora, Inc. | $50.4B | 75 | BUY |
| 601607.SS | Shanghai Pharmaceuticals Holding Co., Ltd | $8.4B | 91 | STRONG BUY |
| HSIC | Henry Schein, Inc. | $9.7B | 79 | BUY |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 96 | STRONG BUY |
| 7459.T | MediPal Holdings Corporation | $3.3B | 87 | STRONG BUY |
| 0874.HK | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.9B | 85 | STRONG BUY |
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd | $3.4B | 80 | BUY |
| 600511.SS | China National Medicines Corporation Ltd. | $2.9B | 98 | STRONG BUY |
Peer medians: ROE 2.8% · P/E 22.2x · Gross margin 47.0%